BioSpace News Archive

Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of neovascular (wet) age-related macular degeneration (nAMD).

VTU Technology GmbH announced today the change of its company name to VALIDOGEN GmbH following a reorganization of VTU Holding GmbH.

Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces that data from a phase I study assessing the safety and tolerability of its lead drug candidate SNF472 in haemodialysis patients has been published in the British Journal of Clinical Pharmacology.

For the second time in less than one week, Dicerna Pharmaceutical has forged a licensing agreement for its GalXC RNAi technology platform. This time Dicerna and Eli Lilly have struck an agreement to use the platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.

Genetic testing has become an important medical standard for families with known histories of hereditary disease. Individuals who choose to go through the mental and emotional process of taking a genetic test and absorbing the potentially life-changing conclusions may be disturbed to find out that results of such tests are not always consistent.

OptiBiotix Health has named Adam Reynolds as Non-Executive Chairman of its new specialist probiotic subsidiary ProBiotix Health Limited. With 14 commercial deals in just under 18 months and a strong deal pipeline in place ProBiotix is well placed to become a stand-alone company.

Eisai Co., Ltd. and MSD K.K., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that the two companies have commenced joint medical and marketing activities for tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in Japan.

Immunicum AB announced today that the Company will participate in and host investor events in October and November.

More than 120 attendees gathered from the 17th to 18th October in Hannover for the European Business Development Conference (EBDC), the yearly biotech partnering event of the German biotechnology industry association BIO Deutschland.

Routine corticosteroid treatment correlates with increased mortality and decreased Traumakine efficacy